Phase III obesity registration trial of tesofensine meets primary and secondary endpoints Dec. 18, 2018
Staten Biotechnology, Novo Nordisk enter collaboration and option agreement in hypertriglyceridemia Dec. 18, 2018
Axovant licenses gene therapies for GM1 and GM2 gangliosidosis from University of Massachusetts Dec. 17, 2018
Rhythm begins phase III trial of setmelanotide in Bardet-Biedl syndrome and Alstrom syndrome Dec. 14, 2018
RSS